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Abstract. 
 
Dystrophin is a multidomain protein that
links the actin cytoskeleton to laminin in the extracellu-
lar matrix through the dystrophin associated protein
(DAP) complex. The COOH-terminal domain of dys-
trophin binds to two components of the DAP complex,
syntrophin and dystrobrevin. To understand the role of
syntrophin and dystrobrevin, we previously generated a
series of transgenic mouse lines expressing dystrophins
with deletions throughout the COOH-terminal domain.
Each of these mice had normal muscle function and dis-
played normal localization of syntrophin and dystro-
brevin. Since syntrophin and dystrobrevin bind to each
other as well as to dystrophin, we have now generated a
transgenic mouse deleted for the entire dystrophin
COOH-terminal domain. Unexpectedly, this truncated
dystrophin supported normal muscle function and as-
sembly of the DAP complex. These results demonstrate
that syntrophin and dystrobrevin functionally associate
with the DAP complex in the absence of a direct link to
dystrophin. We also observed that the DAP complexes
in these different transgenic mouse strains were not
identical. Instead, the DAP complexes contained vary-
ing ratios of syntrophin and dystrobrevin isoforms.
These results suggest that alternative splicing of the
 
dystrophin gene, which naturally generates COOH-
terminal deletions in dystrophin, may function to regu-
late the isoform composition of the DAP complex.
Key words: dystrophin • muscular dystrophy • syntro-
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Introduction
 
Duchenne muscular dystrophy (DMD) is an X-linked re-
cessive disease caused by defects in the dystrophin gene
(Koenig et al., 1987; Emory, 1993). Although the exact
function of dystrophin is unclear, it is postulated to play
both structural and signaling roles in protecting muscle fi-
bers from contraction-induced injury (Zubrzycka-Gaarn
et al., 1988; Ervasti and Campbell, 1991; Cox et al., 1993;
Petrof et al., 1993; Grady et al., 1999). Dystrophin is a 427-
kD multidomain protein that has an NH
 
2
 
-terminal actin
binding motif resembling those in 
 
a
 
-actinin and 
 
b
 
-spectrin
(for review see Amalfitano et al., 1997). The majority of
the dystrophin molecule is a rod-like domain composed
of 24 spectrin-like repeats and 4 hinge regions. Towards
the COOH terminus, dystrophin contains multiple do-
mains that interact with both peripheral and integral mem-
brane proteins known as the dystrophin associated protein
(DAP)
 
1
 
 complex (Ervasti and Campbell, 1991). A WW
domain at the beginning of this region binds to 
 
b
 
-dystro-
glycan and this interaction is stabilized by the adjacent cys-
teine-rich domain (Jung et al., 1995). 
 
b
 
-dystroglycan binds
to 
 
a
 
-dystroglycan, which connects to laminin, linking the
DAP complex to the actin cytoskeleton and the extracellu-
lar matrix (Ibraghimov-Beskrovnaya et al., 1992; Ervasti
and Campbell, 1993). The sarcoglycan complex appears to
stabilize the link between 
 
a
 
-dystroglycan and 
 
b
 
-dystrogly-
can (Araishi et al., 1999).
The link between 
 
b
 
-dystroglycan and dystrophin is
critical for the function of dystrophin, as deletions in the
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 DAP, dystrophin-associated protein;
 
EDL, extensor digitorum longus; HSA, human 
 
a
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cysteine-rich domain of dystrophin eliminate binding to
 
b
 
-dystroglycan and prevent assembly of the sarcoglycan
complex, leading to a severe dystrophy (Suzuki et al.,
1992; Jung et al., 1995; Rafael et al., 1996). The dystrophin
COOH-terminal domain is located adjacent to the cys-
teine-rich domain, and contains an alternatively spliced re-
gion and two coiled-coil motifs (Feener et al., 1989; Bies et
al., 1992; Blake et al., 1995). The alternatively spliced re-
gion binds three isoforms of syntrophin in muscle, while
the coiled-coil motifs bind numerous members of the dys-
trobrevin family (Ahn and Kunkel, 1995; Dwyer and Froeh-
ner, 1995; Suzuki et al., 1995; Yang et al., 1995; Sadoulet-
Puccio et al., 1997). The dystrobrevins display significant
homology with the COOH-terminal region of dystrophin,
and the larger dystrobrevin isoforms also bind to the syn-
trophins (Butler et al., 1992; Wagner et al., 1993; Yoshida
et al., 1995). The importance and functional significance of
syntrophin and dystrobrevin remains largely unknown, al-
though they may be involved in cell signaling pathways
(Bredt, 1999; Grady et al., 1999).
Three isoforms of syntrophin (
 
a
 
1, 
 
b
 
1, and 
 
b
 
2), which are
encoded by separate genes, bind dystrophin in skeletal
muscle (Adams et al., 1995; Ahn et al., 1996; Peters et al.,
1997a). The syntrophins contain a PDZ domain that binds
multiple proteins including neuronal nitric oxide synthase
(nNOS), sodium channels, stress-activated protein kinase-3,
and a microtubule-associated serine/threonine kinase (Bren-
man et al., 1996; Gee et al., 1998; Schultz et al., 1998; Hase-
gawa et al., 1999; Lumeng et al., 1999a). However, these
interactions may not be critical for muscle fiber stability,
since 
 
a
 
1-syntrophin knockout mice have no overt signs of
dystrophy (Kameya et al., 1999). While 
 
a
 
1- and 
 
b
 
1-syntro-
phin are localized along the sarcolemma, 
 
b
 
2-syntrophin is
normally localized at the troughs of the neuromuscular
junction (Kramarcy and Sealock, 2000).
The dystrobrevin family is encoded by at least two
genes, 
 
a
 
 and 
 
b
 
, although only the 
 
a
 
-dystrobrevin gene is
expressed at significant levels in muscle (Wagner et al.,
1993; Peters et al., 1997b; Blake et al., 1998; Puca et al.,
1998). Several isoforms of 
 
a
 
-dystrobrevin are expressed in
muscle due to alternative splicing of the primary transcript
(Blake et al., 1996; Sadoulet-Puccio et al., 1996; Peters et
al., 1998). 
 
a
 
-dystrobrevin-1 resides primarily, but not ex-
clusively, at the neuromuscular junction (NMJ) and
contains an extended COOH terminus that is tyrosine
phosphorylated. 
 
a
 
-dystrobrevin-2 has a shorter COOH
terminus, and is found along the entire sarcolemma (Bala-
subramanian et al., 1998; Nawrotzki et al., 1998; Peters et
al., 1998). The shortest isoform, 
 
a
 
-dystrobrevin-3, lacks
both the syntrophin and dystrophin binding sites, but little
is known of the expression of this isoform in muscle. As
with all components of the DAP complex, syntrophin and
dystrobrevin are largely absent from the sarcolemma of
dystrophin-deficient 
 
mdx
 
 mice and Duchenne muscular
dystrophy patients (Ohlendieck and Campbell, 1991).
However, mice deficient for dystrobrevin display a moder-
ately severe muscular dystrophy with a variety of features
different from those of the 
 
mdx
 
 mouse. With the exception
of nNOS, all known components of the DAP complex are
present on the sarcolemma of dystrobrevin-deficient mice.
These mice display no signs of damage to the sarcolemma,
implicating a distinct mechanism of dystrophy indepen-
 
dent of the role of dystrophin (Grady et al., 1999). Dystro-
brevin, dystrophin, and utrophin also appear to be required
for postnatal maturation of neuromuscular junctions (Grady
et al., 2000; Rafael et al., 2000).
To determine the importance of syntrophin and dystro-
brevin binding to dystrophin, we previously generated
transgenic 
 
mdx
 
 mouse strains expressing dystrophins de-
leted for either the syntrophin or the dystrobrevin binding
domain (Rafael et al., 1994, 1996). These mice displayed
normal muscle function and essentially normal localiza-
tion of syntrophin, dystrobrevin, and nNOS (Rafael et al.,
1994, 1996; Straub et al., 1997; Crosbie et al., 1998). Thus,
while dystrobrevin appears to protect muscle from dam-
age (Grady et al., 1999), removal of the dystrobrevin bind-
ing site from dystrophin does not result in a dystrophy.
Subsequent studies revealed that syntrophin and dystro-
brevin bind each other in addition to dystrophin, so that
removal of only one of the two binding sites on dystrophin
might not sever the link between dystrophin, syntrophin
and dystrobrevin. To explore the nature of the interaction
between dystrophin and these DAP components, we gen-
erated new transgenic 
 
mdx
 
 mouse lines that express a dys-
trophin lacking both the syntrophin and dystrobrevin
binding domains. Surprisingly, these transgenic mice dis-
played normal muscle function. Our results also show that
this truncated dystrophin stabilized assembly of the entire
DAP complex. These results demonstrate that syntrophin
and dystrobrevin can bind to the DAP complex indepen-
dently from dystrophin and that this association is suffi-
cient to prevent dystrophy.
 
Materials and Methods
 
Dystrophin Transgenic mdx Mice
 
The bases encoding amino acids 3402–3675 (corresponding to exons
71–78) were deleted from the full length murine dystrophin cDNA (se-
quence data available from EMBL/GenBank/DDBJ under accession No.
M68859) by recombinant PCR, leaving the last three amino acids (exon
79) of the dystrophin protein unaltered. This dystrophin 
 
D
 
71–78 cDNA
was cloned into an expression vector containing bases 
 
2
 
2139 to 
 
1
 
239 of
the human 
 
a
 
-skeletal actin (HSA) promoter (Brennan and Hardeman,
1993). A splice acceptor from the SV40 VP1 intron (isolated as a 400 bp
HindIII/XbaI fragment from pSVL; Amersham Pharmacia Biotech) was
inserted immediately 3
 
9
 
 of the HSA fragment, and the SV40 polyadenyla-
tion signal (isolated as a BamHI fragment from pCMV
 
b
 
; MacGregor and
Caskey, 1989) was inserted 3
 
9
 
 of the dystrophin cDNA. The excised dys-
trophin 
 
D
 
71–78 expression cassette was injected into wild-type C57Bl/
10 
 
3
 
 SJL/J F
 
2
 
 hybrid embryos, and F
 
0
 
 mice were screened by PCR. Five
positive F
 
0
 
’s were backcrossed onto the C57Bl/10
 
mdx 
 
background, and
most further studies focused on the line with the most uniform expression
levels. Some studies used previously described transgenic 
 
mdx
 
 mice that
express dystrophin constructs deleted approximately for exons 71–74
(
 
D
 
71–74) or exons 75–78 (
 
D
 
75–78), which remove amino acids 3402–3511
and 3528–3675, respectively (Rafael et al., 1996). Transgenic 
 
mdx
 
 line
Dp71 expresses the Dp71 isoform of dystrophin in striated muscle (Cox et
al., 1994).
 
Morphology
 
Quadriceps, soleus, extensor digitorum longus (EDL), tibialis anterior,
and diaphragm muscles were removed from mice, frozen in liquid nitro-
gen cooled O.C.T. embedding medium (Tissue-Tek), and cut into 7-
 
m
 
m
sections. After fixing in 3.7% formaldehyde, sections were stained in he-
matoxylin and eosin–phloxine. Stained sections were imaged with a Nikon
E1000 microscope connected to a Spot-2 CCD camera. To determine the
percentage of fibers containing central nuclei, the number of muscle fibers 
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with centrally-located nuclei was divided by the total number of muscle fi-
bers.
 
Evans Blue Assays
 
4-mo-old control and 
 
D
 
71–78 mice were analyzed after injection with
Evans blue, as described previously (Straub et al., 1997). In brief, mice
were tail vein–injected with 150 
 
m
 
l of a solution containing 10 mg/ml
Evans blue dye in PBS (150 mM NaCl, 50 mM Tris, pH 7.4). After 3 h, the
animals were euthanized and mouse tissues were either fixed in 3.7%
formaldehyde/0.5% glutaraldehyde to observe gross dye uptake, or frozen
unfixed in O.C.T. embedding medium. To examine Evans blue uptake by
individual fibers, 7-
 
m
 
m-thick frozen sections were fixed in cold acetone
and analyzed by fluorescence microscopy.
 
Immunofluorescence
 
Quadriceps and diaphragm muscles from C57Bl/10, 
 
mdx
 
, and 
 
D
 
71–78
mice were removed, frozen in O.C.T. embedding medium, and cut into
7-
 
m
 
m sections. Immunofluorescence was performed with previously de-
scribed antibodies against dystrophin (NH
 
2
 
 terminus; Rafael et al., 1996),
 
a
 
1-syntrophin (SYN17; Peters et al., 1997a), 
 
b
 
1-syntrophin (Peters et al.,
1997a), 
 
a
 
-dystrobrevin-1 (
 
a
 
DB670), 
 
a
 
-dystrobrevin-2 (
 
a
 
DB2; Peters et
al., 1998), and utrophin (Lumeng et al., 1999c). After incubation with pri-
mary antibodies, cryosections were incubated with an FITC-conjugated
goat anti–rabbit secondary antibody and fluorescent images were viewed
on a Nikon E1000 microscope. Antibodies to 
 
a
 
-sarcoglycan (Rabbit 98),
 
b
 
-sarcoglycan (Goat 26), 
 
g
 
-sarcoglycan (Rabbit 245), 
 
d
 
-sarcoglycan (Rab-
bit 215), sarcospan (Rabbit 235), 
 
a
 
-dystroglycan (Goat 20), 
 
b
 
-dystrogly-
can (AP 83), or nNOS (Rabbit 200) have been described previously (Duc-
los et al., 1998). Cy3-conjugated secondary antibodies were used and
images were viewed on a Bio-Rad MRC-600 laser scanning confocal mi-
croscope. All digitized images were captured under identical conditions.
 
Measurements of Contractile Properties
 
Contractile properties of muscles from 6-mo-old 
 
D
 
71–78 transgenic mice
were compared with those of C57Bl/10 wild-type and 
 
mdx
 
 mice using
methods described previously (Lynch et al., 1997). The samples included
eight muscles each from the EDL, soleus, and diaphragm. Mice were
deeply anesthetized with avertin and each muscle was isolated and dis-
sected free from the mouse. After removal of the limb muscles, the mice
were euthanized with the removal of the diaphragm muscle. The muscles
were immersed in a bath filled with oxygenated buffered mammalian
Ringer’s solution (137 mM NaCl, 24 mM NaHCO
 
3
 
, 11 mM glucose, 5 mM
KCl, 2 mM CaCl
 
2
 
, 1 mM MgSO
 
4
 
, 1 mM NaH
 
2
 
PO
 
4
 
, and 0.025 mM tu-
bocurarine chloride, pH 7.4). For each muscle, one tendon was tied to a
servomotor and the other tendon to a force transducer. Muscles were
stretched from slack length to the optimal length for force development
and then stimulated at a frequency that produced absolute isometric teta-
nic force (mN). After the measurements of the contractile properties, the
muscles were removed from the bath, blotted and weighed to determine
muscle mass. Specific force (kN/m
 
2
 
) was calculated by dividing absolute
force by total fiber cross sectional area.
 
Muscle Membrane Isolation
 
Muscle microsomes from 12–14-mo-old C57Bl/10, 
 
mdx
 
, 
 
D
 
71–78, 
 
D
 
71–74,
 
D
 
75–78, and Dp71 mice were prepared as described previously (Ohlen-
dieck et al., 1991a). In brief, skeletal muscle was homogenized in 7.5-vol
homogenization buffer plus protease inhibitor Complete (Boehringer).
The homogenate was centrifuged at 14,000 
 
g
 
 for 15 min to remove cellular
debris. The supernatant was filtered through cheesecloth and spun at
142,000 
 
g
 
 for 37 min to collect microsomes. The microsome pellet was re-
suspended in KCl wash buffer (0.6 M KCl, 0.3 M sucrose, 50 mM Tris-
HCl, pH 7.4) plus protease inhibitors and recentrifuged at 142,000 
 
g
 
 for 37
min to obtain KCl-washed microsomes. The final pellet was resuspended
in 0.3 M sucrose and 20 mM Tris-maleate, pH 7.0. Samples were quanti-
fied by the Coomassie Plus Protein Assay Reagent (Pierce Chemical Co.)
and equivalent protein loading was verified by SDS-PAGE. KCl-washed
microsomes were analyzed by Western blot using antibodies against 
 
b
 
2-
syntrophin (Peters et al., 1994), pan syntrophin (Froehner et al., 1987),
nNOS (Transduction Laboratories), 
 
b
 
-dystroglycan, 
 
a
 
-sarcoglycan (No-
vocastra Laboratories), and other proteins described above.
 
Results
 
Generation of Dystrophin 
 
D
 
71–78 Transgenic Mice
 
To test the function of a dystrophin protein lacking both
the syntrophin and dystrobrevin binding sites, we pre-
pared a cDNA expression vector deleted for the COOH-
terminal domain (corresponding to exons 71–78; Fig. 1 A).
The structure of several dystrophin transgenic constructs
we had previously tested are also shown for comparison.
Mice expressing the dystrophin 
 
D
 
71–78 transgene were
crossed onto the 
 
mdx
 
 background and dystrophin levels
were analyzed by Western blotting. The expression of the
dystrophin 
 
D
 
71–78 transgene in skeletal muscle was 
 
z
 
10-
fold higher than endogenous dystrophin (Fig. 1 B). Immu-
nofluorescent staining of quadriceps muscle using an anti-
body against the NH
 
2
 
-terminus of dystrophin revealed
that the 
 
D
 
71–78 protein was localized to the sarcolemma,
similar to wild-type dystrophin (Fig. 1 C). Dystrophin
 
D
 
71–78 expression was also found to be uniform in the dia-
phragm, EDL, and soleus muscles, but the tibialis anterior
muscle displayed a mosaic expression pattern and was not
further analyzed (data not shown). The human skeletal
muscle 
 
a
 
-actin promoter used in this study was not ex-
pressed in either smooth or cardiac muscle (data not
shown).
 
Morphology of Dystrophin 
 
D
 
71–78 Mice Appears Normal
 
We initially analyzed transgenic 
 
mdx
 
 mouse muscle tissues
for morphological signs of dystrophy. Hematoxylin and
eosin–stained limb and diaphragm skeletal muscle sections
of dystrophin 
 
D
 
71–78 mice revealed none of the signs of fi-
brosis, necrotic fibers, or mononuclear cell infiltration that
were apparent in age-matched 
 
mdx
 
 controls (Fig. 2, A and
B, and data not shown). NMJs of transgenic mice stained
with rhodamine-labeled 
 
a
 
-bungarotoxin consistently ap-
peared normal in contrast to the varying degrees of
postsynaptic folding observed in 
 
mdx
 
 NMJs (Fig. 2 C).
 
Mdx
 
 muscle fibers have previously been shown to be
highly permeable to the vital dye Evans blue in vivo, re-
flecting damage to the dystrophic fiber sarcolemma (Mat-
suda et al., 1995). Skeletal muscle fibers from dystrophin
 
D
 
71–78 mice, like wild-type animals, were not permeable
to Evans blue dye (Fig. 2, D and E).
 
Analysis of Centrally Nucleated Muscle Fibers
 
Another hallmark of dystrophy in 
 
mdx
 
 mice is the pres-
ence of large numbers of centrally-nucleated muscle fi-
bers, reflecting cycles of fiber degeneration and regenera-
tion (Torres and Duchen, 1987; Bockhold et al., 1998). To
estimate the degree of myofiber regeneration occurring in
 
D
 
71–78 transgenic mice, we counted centrally nucleated fi-
bers from a variety of muscle groups in age-matched wild-
type, 
 
mdx
 
, and 
 
D
 
71–78 mice (Table I). By 4 mo of age,
71% of muscle fibers in 
 
mdx
 
 quadriceps muscles contained
central nuclei, whereas wild-type muscles had 
 
,1%. Inter-
estingly, 4-mo-old dystrophin D71–78 quadriceps muscles
displayed z1% central nuclei, indicating that very little, if
any, regeneration was occurring. However, when 1-yr-old
mice were compared, an increase in centrally nucleated fi-
bers became apparent. Quadriceps muscles from D71–78
mice contained 10% centrally nucleated fibers, althoughThe Journal of Cell Biology, Volume 150, 2000 1402
diaphragm muscles still displayed ,1%. EDL and soleus
muscles displayed 5 and 8% centrally nucleated fibers, re-
spectively. For comparison, 1-yr-old wild-type mice had
,1% centrally nucleated fibers in both limb and dia-
phragm muscles. Furthermore, 1-yr-old mdx limb muscles
had 60% centrally nucleated fibers, whereas the dia-
phragm had 35%.
Our previous studies of transgenic mice expressing dys-
trophins deleted for exons 71–74 (D71–74) or exons 75–78
(D75–78) revealed no increase in the numbers of centrally
nucleated fibers by 4 mo of age (Rafael et al., 1996). To
contrast these mice with the D71–78 transgenics, central
nuclei counts were performed on 15-mo-old D71–74 and
D75–78 mice. We found that these animals had central nu-
clei counts in between those of wild-type and D71–78 mice.
The D71–74 and D75–78 mice had 5 and 8% centrally nu-
cleated fibers in quadriceps, respectively (Table I).
Contractile Properties
Compared with muscles of wild-type mice, those from mdx
mice displayed a significant amount of necrosis, fibrosis,
and infiltrating mononuclear cells. mdx skeletal muscles
also displayed a loss of specific force–generating capacities
when muscles were stimulated to contract in vitro, provid-
ing an extremely sensitive and quantitative measurement
of the dystrophic process (Fig. 3 A). In contrast, dystro-
phin D71–78 mice had no major abnormalities when sub-
jected to the same analysis (Fig. 3 B). Muscle mass for
both EDL and diaphragm were not significantly different
between dystrophin D71–78 and wild-type mice, whereas
dystrophin D71–78 soleus muscles were slightly hypertro-
phied. When stimulated to contract, all three muscle
groups displayed specific forces not significantly different
from wild-type (P , 0.05). These results demonstrate that
the dystrophin D71–78 protein has essentially the same
functional capacity as the full-length protein.
Localization of the DAP Complex in D71–78 Mice
Immunofluorescent analysis of the peripheral DAP com-
plex revealed a1-syntrophin, b1-syntrophin, a-dystrobre-
vin-1, and a-dystrobrevin-2 to be localized at the sarco-
lemma with dystrophin, despite the lack of syntrophin and
dystrobrevin binding sites in the transgene-encoded dys-
trophin (Fig. 4). a1-syntrophin levels were similar between
wild-type and D71–78 mice. However, the levels of b1-syn-
trophin were elevated at the membrane in D71–78 mice,
particularly in those fibers that normally express signifi-
cant levels of this isoform. a-dystrobrevin-1 was primarily
located at the NMJ in wild-type mice, and was exclusively
located at the NMJs in mdx mice. Surprisingly, in dystro-
phin D71–78 mice, higher levels of a-dystrobrevin-1 were
observed at the sarcolemma than in wild-type mice. The
Figure 1. Generation of dys-
trophin  D71–78 transgenic
mdx mouse. (A) Shown are
the dystrophin transgenic ex-
pression vectors that contain
Dp71 and full-length cDNAs
deleted for the indicated ex-
ons. The binding sites for b-dys-
troglycan (b-DG), syntro-
phin (Syn), and dystrobrevin
(Db) are delineated relative
to the exon boundaries of the
dystrophin gene. Exon 79 en-
codes only three amino acids
and therefore is not shown.
Dystrophin structural motifs
are also indicated that in-
clude the WW, EF1, EF2,
ZZ, and coiled coil (CC) 1
and 2 domains. The first half
of the WW domain is en-
coded on exon 62. All con-
structs contain either a
mouse muscle creatine kinase [MCK] or the HSA promoter, the SV40 VP1 intron (intron), and the SV40 poly-adenylation site (“A”).
(B) Western blot analysis of total skeletal muscle proteins from wild-type, mdx, and dystrophin D71–78 mice using an NH2-terminal spe-
cific dystrophin antibody. (C) Immunofluorescent staining for dystrophin in muscle quadriceps reveals uniform expression in wild-type
and dystrophin D71–78 mice. Scale bar, 50 mm.
Table I. Percentage of Centrally Nucleated Fibers in Mouse 
Skeletal Muscles
Line Age Quad Dia TA EDL Soleus
mo %
C57/Bl10 4 ,1 ,1N DN D N D
mdx 47 15 8 N D N D N D
71–78 4 1 ,1N DN D N D
C57/Bl10 12 ,1 ,1 ,1 ,1 ,1
mdx 12 65 35 58 50 61
71–78 12 10 ,1N D 5 8
71–74 15 5 ,1 ,1 ,1N D
75–78 15 8 ,1427
Quad, quadriceps; Dia, diaphragm; TA, tibialis anterior.Crawford et al. Function of the Dystrophin COOH Terminus 1403
D71–78 mice also displayed a slight increase in utrophin
localization along the sarcolemma, but this increase was
less than the increase in mdx fibers. Immunofluorescent
localization of the sarcoglycans, a- and b-dystroglycan,
sarcospan, and nNOS in D71–78 mice revealed no differ-
ences in the expression of these proteins when compared
with wild-type mice (Fig. 5). The proper localization of
these proteins to the sarcolemma indicated that mem-
brane targeting of the DAP complex components can
proceed in the absence of the COOH-terminal domain of
dystrophin.
DAP Complex Protein Levels
To examine the levels of the DAP complex members that
associate with dystrophin, muscle microsomes were pre-
pared from wild-type and dystrophin D71–78 mice and an-
alyzed by Western blotting (Fig. 6). This approach can
provide data on the relative abundance of individual DAP
complex members in muscles of separate lines of mice.
Slightly elevated levels of b-dystroglycan were detected in
dystrophin  D71–78 mice, which we have previously ob-
served whenever dystrophin is overexpressed (Cox et al.,
1993; Rafael et al., 1994). Isoforms of syntrophin and dys-
Figure 2. Dystrophin D71–78 skeletal
muscles are morphologically similar to
age-matched wild-type muscles. He-
matoxylin and eosin staining of quadri-
ceps shows no signs of necrosis or fi-
brosis in D71–78 mice that is apparent
in mdx mice (A, 4-mo-old mice; B, 1-yr-
old mice). (B) Occasional fibers in
1-yr-old D71–78 mice contain central
nuclei. (C) Labeling of NMJs reveals
no abnormalities in D71–78 transgenic
muscles in comparison to wild-type
muscles. (D) Evans blue dye is ex-
cluded from hind limb skeletal muscle
fibers in wild-type and D71–78, but not
mdx mice. (E) Cryosections from dia-
phragm muscle show Evans blue dye
positive fibers only in mdx mice. Scale
bars, 50 mm.The Journal of Cell Biology, Volume 150, 2000 1404
trobrevin were present at slightly different levels when the
dystrophin D71–78 membranes were compared with those
from wild-type mice. a1-syntrophin and b2-syntrophin lev-
els were lower than in wild-type mice, whereas the level of
b1-syntrophin was elevated. Although there was approxi-
mately the same amount of a-dystrobrevin-2, there were
elevated levels of a-dystrobrevin-1 in D71–78 microsomes.
A reduction in nNOS was observed in dystrophin D71–78
muscle, indicating that nNOS binds weakly to the DAP
complex in D71–78 mice. Levels of a-sarcoglycan were
similar in all lines tested, and provided an internal control
for protein loading.
Since some DAP complex members exhibited isoform
changes in D71–78 mice, we were prompted to look at pu-
rified microsomes from dystrophin D71–74 and D75–78
Figure 3. Contractile properties of EDL, soleus, and diaphragm
muscles in wild-type, mdx, and dystrophin D71–78 mice. Muscle
mass and specific force for mdx (A) and D71–78 (B) muscles
were charted as a percentage of wild-type values. Significant dif-
ferences (P , 0.05) are marked with an asterisk (*).
Figure 4. Peripheral DAP
complex members are local-
ized to the sarcolemma in
quadriceps muscle of wild-
type (wt) and D71–78 mice.
Immunofluorescent staining
was performed using antibod-
ies against a1-syntrophin (a1-
syn),  b1-syntrophin (b1-syn),
a-dystrobrevin-2 (a-Db-2),
a-dystrobrevin-1 (a-Db-1),
and utrophin. a-dystrobrevin-2
is primarily found at the sar-
colemma in wild-type muscles.
mdx muscle sections have no
a1-syntrophin or a-dystrobre-
vin-2 staining at the sarco-
lemma, but a-dystrobrevin-1
remains at the NMJ. Elevated
levels of b1-syntrophin were
observed in regenerating fi-
bers of mdx mice. Utrophin
sections were double labeled
with a-bungarotoxin (a-BT)
to identify NMJs. Utrophin
was expressed at the sarco-
lemma and in capillaries sur-
rounding muscle fibers. Scale
bars, 50 mm.Crawford et al. Function of the Dystrophin COOH Terminus 1405
mice. Transgenic mdx mice that express the dystrophin
isoform Dp71 in muscle were also included in this study
since these dystrophic mice have the DAP complex
present at the sarcolemma (Cox et al., 1994; Straub et al.,
1997; Crosbie et al., 1998). a1-syntrophin levels were
lower in all four transgenic lines compared with wild-type
mice. Surprisingly, b1-syntrophin was absent in D71–74
microsomes but was highly overexpressed in D75–78 and
Dp71 microsomes. The D71–74 microsomes had equiva-
lent b2-syntrophin levels when compared with wild-type
microsomes, but this isoform of syntrophin was reduced in
both D75–78 and Dp71 microsomes. A pan syntrophin an-
tibody, which detects all three isoforms of syntrophin, con-
firmed the upregulation of syntrophin in D75–78 and Dp71
microsomes. Similar to D71–78, a-dystrobrevin-1 was ele-
vated in all dystrophin transgenic microsome preparations.
However, in comparison with wild-type, a-dystrobrevin-2
was higher in D71–74 and D75–78, but equal in Dp71 mi-
crosomes. Contrary to the D71–78 mice, deleting either ex-
ons 71–74 or 75–78 restored nNOS to wild-type levels.
However, Dp71 mice, which lack the NH2-terminal and
rod domains of dystrophin, did not retain nNOS in the mi-
Figure 5. Immunofluores-
cent localization of the
sarcoglycan complex (a-, b-,
g-, and d-SG), dystroglycan
complex (a- and b-DG), sar-
cospan (SSPN) and nNOS in
wild-type and D71–78 skele-
tal muscle. All members of
the complex are localized
uniformly at the sarco-
lemma. Scale bar, 50 mm.
Figure 6. Western blot analysis of KCl-washed skeletal muscle
microsome preparations from wild-type, mdx, D71–78, D71–74,
D75–78, and Dp71 mice. 50 mg of microsome protein was ana-
lyzed by Western blot with antibodies against a-dystrobrevin-1
(a-Db-1), a-dystrobrevin-2 (a-Db-2), a1-syntrophin, b1-syntro-
phin,  b2-syntrophin, pan syntrophins, nNOS, b-dystroglycan
(b-DG), a-sarcoglycan (a-SG), and utrophin.The Journal of Cell Biology, Volume 150, 2000 1406
crosome fractions. Previous studies have also shown that
utrophin is upregulated in mdx and Dp71 mice (Ohlen-
dieck et al., 1991b; Tanaka et al., 1991; Cox et al., 1994).
Therefore, we have compared utrophin levels in all trans-
genic lines and have found that D71–78, D71–74, and D75–
78 mice do not have the elevated levels seen in mdx and
Dp71 mice.
Discussion
The dystrophin-associated protein complex plays a critical
role in protecting muscle cells from damage, but the func-
tion of each component of the DAP complex remains un-
clear. Integral membrane DAPs, such as b-dystroglycan
and the sarcoglycans, appear to play primarily a structural
role in linking the muscle cytoskeleton, via dystrophin, to
the extracellular matrix. This structural link is critical for
protecting muscle fibers from contraction-induced injuries
and sarcolemmal damage (Petrof et al., 1993; Faulkner et
al., 1997; Lynch et al., 2000). The importance of this link is
illustrated by the observation that in-frame deletions
within the dystroglycan binding domain of dystrophin
(Dcys) inactivate the protective functions of the DAP
complex and result in a dystrophy equivalent to if not
worse than that resulting from the absence of dystrophin
(Rafael et al., 1996). Similarly, mutations in sarcoglycan
genes that destabilize the entire sarcoglycan complex typi-
cally result in a pathology resembling that resulting from
dystrophin deficiency (Bönnemann et al., 1995; Noguchi et
al., 1995; Nigro et al., 1996; Duclos et al., 1998).
In contrast, little is known about the peripheral dystro-
phin complex, and it is unclear whether it plays a structural
and/or signaling role. Only one patient has been described
with a deletion limited to the syntrophin and dystrobrevin
binding domains of dystrophin. This patient (CM) had a
deletion of exons 72–79 and displayed a mild Becker mus-
cular dystrophy phenotype (McCabe et al., 1989; Cham-
berlain, J.S., unpublished observations). However, no data
is available on the expression of dystrophin or other DAPs
in this patient. We have studied the interaction between
dystrophin, the syntrophins, and the dystrobrevins by dis-
rupting the peripheral complex binding sites on dystrophin
in vivo in mdx mice.
We found that the dystrophin D71–78 protein supported
normal muscle function in mdx mice up to at least 6 mo of
age, although very mild signs of muscle regeneration were
observed in a subset of muscle groups in animals older than
1 yr. 6-mo-old D71–78 mice displayed normal muscle mass,
morphology, NMJ structure, membrane integrity, and spe-
cific force generating capacities in at least three different
muscle groups, including the diaphragm (Figs. 2 and 3; and
Table I). Despite deletion of the binding sites on dystro-
phin for syntrophin and dystrobrevin, muscles from the
D71–78 mice displayed an overtly normal DAP complex
that included family members of both of these peripheral
complex proteins, as well as nNOS (Figs. 4 and 5).
Because the lack of dystrophin in mdx mice destabilizes
the entire DAP complex, it is clear that components of the
DAP complex are required to localize syntrophin and dys-
trobrevin at the sarcolemma (Ohlendieck and Campbell,
1991). Our observation that syntrophin and dystrobrevin
assemble into a functional DAP complex in the absence of
the dystrophin COOH-terminal domain provides several
important insights into the structure and function of the
DAP complex. First, this study indicates that dystrobrevin
and/or syntrophin bind to another component of the DAP
complex besides dystrophin. Second, the normal pheno-
type in the D71–78 mice demonstrates that a link between
dystrophin and syntrophin or dystrobrevin is not critical
for the function of the DAP complex.
Although young adult D71–78 mice displayed a normal
phenotype, old transgenic mice displayed a slight increase
in the presence of centrally nucleated fibers, suggesting a
low level of limb muscle degeneration and regeneration.
However, there were no signs of increased fibrosis or
mononuclear cell infiltration, nor was there an increase in
basophilic or hypercontracted fibers (Fig. 2 B, and data
not shown). The number of centrally nucleated (and thus
regenerated) muscle fibers was also slightly higher in 1-yr-
old D71–78 mice than in either the D71–75 or D75–78 mice,
indicating that removal of both the syntrophin and the
dystrobrevin binding sites is slightly more detrimental
than removal of individual sites. Interestingly, this low-
level muscle regeneration was only observed in limb mus-
cles of older transgenic mdx mice (Table I). Diaphragm
muscle of 1-yr-old D71–78 transgenic mdx mice displayed
no pathology, even though the diaphragm is the most se-
verely affected muscle group in mdx mice (Stedman et al.,
1991; Cox et al., 1993; Lynch et al., 1997). These results
suggest that the peripheral DAPs play slightly different
roles in different muscle types, and that these roles may re-
quire unique combinations of syntrophin and/or dystro-
brevin isoforms.
A striking observation from the various lines of trans-
genic mice was that although all of the COOH-terminal
deletions supported assembly of an overtly normal DAP
complex, shifts were detected in the relative abundance of
the separate dystrobrevin and syntrophin isoforms. Each
of the transgenic mouse strains analyzed in Fig. 6 dis-
played an upregulation of a-dystrobrevin-1. In contrast,
levels of a-dystrobrevin-2 displayed more modest changes
by western analysis, with the least variation from wild-type
found in the D71–78 muscles. Since a-dystrobrevin-1 is up-
regulated and redistributed in muscles expressing the trun-
cated dystrophins (Figs. 4 and 6), we suggest that the alter-
nate (non COOH-terminal dystrophin) binding site within
the DAP complex may have a higher affinity for this iso-
form. Similarly, the COOH-terminal domain of dystrophin
may have a higher affinity for a-dystrobrevin-2. Disrup-
tion of the interaction between the dystrophin COOH-ter-
minal domain and a-dystrobrevin-2 may also make the
alternate binding site more accessible to binding by a-dys-
trobrevin-1. This latter isoform has a tyrosine phosphory-
lated and extended COOH-terminal domain which might
otherwise hinder access to the alternate binding site (Wag-
ner et al., 1993; Blake et al., 1996; Balasubramanian et al.,
1998; Peters et al., 1998).
The reduced level of a1-syntrophin in membrane prep-
arations from D71–78 mice suggests that efficient binding
of a1-syntrophin to the DAP complex requires an intact
and functional dystrophin COOH terminus. Reductions of
a1-syntrophin were associated with an upregulation of
b1-syntrophin in each transgenic line studied, except for
the line expressing a dystrophin deleted for the syntrophinCrawford et al. Function of the Dystrophin COOH Terminus 1407
binding domain (71–74). In this latter case, reduced levels
of a1-syntrophin were associated with a marked upregula-
tion of b2-syntrophin (Fig. 6). Pan-syntrophin antibodies
revealed a relatively constant level of syntrophin expres-
sion in all mice studied, except for a peculiar upregulation
in the D75–78 and Dp71 mice that was due to a large in-
crease in b1-syntrophin expression coupled with a slight
decrease in b2-syntrophin. The reduction of nNOS in mi-
crosome preparations from D71–78 mice could be a sec-
ondary result of weak a1-syntrophin interactions with the
DAP complex. The loss of nNOS in Dp71 mice, which
have normal levels of a1-syntrophin, may be a secondary
consequence of the extensive pathology in these animals.
Also, although Dp71 mice display elevated levels of utro-
phin, a significant increase was not observed in the D71–78
mice, indicating that ectopic utrophin expression does not
account for syntrophin and dystrobrevin isoform changes.
The highest utrophin levels were observed in mdx mice,
which express very low levels of all DAP complex mem-
bers (Fig. 6).
The D71–74 and D71–78 deletions we studied are ex-
pressed in humans and mice as naturally occurring iso-
forms of dystrophin (Feener et al., 1989; Bies et al., 1992;
Tinsley et al., 1993). Dp71 is also a natural isoform ex-
pressed in non-muscle tissues including many cell types in
the brain (Lederfein et al., 1993; Lumeng et al., 1999b;
Sarig et al., 1999). Our results suggest that alternative
splicing of the dystrophin COOH-terminal domains and
expression of the smaller dystrophin transcripts may be
important for regulating which isoforms of syntrophin and
dystrobrevin assemble with the DAP complex in muscle or
nonmuscle tissues.
Our results provide additional clues as to the potential
signaling role of the peripheral DAP complex. The data in
Fig. 6 suggest that a reduced association of nNOS with the
DAP complex does not by itself contribute significantly to
the dystrophic process. Mice deficient in nNOS have no
abnormal muscle phenotype, and a complete lack of nNOS
does not overtly exacerbate the mdx phenotype (Chao et
al., 1998; Crosbie et al., 1998). These data indicate that
nNOS is involved in functions separate from stabilizing
the sarcolemma. Previous studies have suggested that
nNOS plays a role in preventing ischemic damage in exer-
cising muscles (Thomas et al., 1998). Mice with mutations
in either dystrobrevin or syntrophin express a DAP com-
plex that lacks nNOS, but only the dystrobrevin-deficient
mice display a dystrophic phenotype (Grady et al., 1999;
Kameya et al., 1999). In these dystrobrevin mutants, the
remaining DAP complex is intact, indicating that the
mode of dystrophy is likely different from that in mice
lacking dystrophin or a sarcoglycan (Matsumura et al.,
1993; Duclos et al., 1998; Hack et al., 1998; Straub et al.,
1998; Araishi et al., 1999).
The ability to sever the connection between dystrophin
and dystrobrevin without causing dystrophy demonstrates
that the function of dystrobrevin does not depend on a
tight connection to dystrophin. Such a tight connection
would be expected for a protein playing a mechanical role
facilitating force transduction between the muscle cyto-
skeleton and the extracellular matrix. Our results are
therefore compatible with the suggestion by Grady et al.
(1999) that dystrobrevin plays a signaling role in muscle.
These observations are also in marked contrast to the se-
vere muscle pathology present in mice with dystrophin de-
letions that remove the binding site for b-dystroglycan
(Rafael et al., 1996).
Our results suggest that models for the organization of
the DAP complex need to reflect an interaction between
syntrophin and/or dystrobrevin and an additional protein
besides dystrophin (Fig. 7). Utrophin is not a likely candi-
date, as we did not observe a correlation between utrophin
levels and the expression of dystrobrevin and syntrophin
isoforms (Figs. 4 and 6). We also cannot formally rule out
the possibility of another binding site on dystrophin, al-
though to date none have been detected. Yoshida et al.
(2000) detected subcomplexes between dystrobrevin and
the sarcoglycans when purified DAP complexes were frac-
tionated after incubation in various conditions of ionic
Figure 7. Schematic diagrams of the dystrophin-associated protein complex. (A) Structure of the DAP complex in normal mouse skele-
tal muscle. This model reflects the presence of an interaction between dystrobrevin and the sarcoglycans and/or b-dystroglycan, in addi-
tion to dystrophin, as discussed in the text. Note that alternate binding sites to as yet unidentified DAP components are possible. (B)
Proposed structure of the DAP complex in dystrophin D71–78 transgenic mdx mice. An interaction between dystrobrevin and the inte-
gral membrane components of the DAP complex is sufficient to localize syntrophin and dystrobrevin to the membrane in the absence of
the dystrophin COOH-terminal domain.The Journal of Cell Biology, Volume 150, 2000 1408
strength. Dystrobrevin might therefore attach to the DAP
complex in the D71–78 mice via an interaction with the
sarcoglycan complex, although the binding of either syn-
trophin or dystrobrevin to b-dystroglycan cannot be ex-
cluded. Another potential candidate to bind dystrobrevin
or syntrophin is aquaporin-4, which was recently shown to
be absent from the sarcolemma of a1-syntrophin knock-
out mice (Yokota et al., 2000). The identification of addi-
tional binding sites for syntrophin and dystrobrevin in the
DAP complex should lead to a greater understanding of
the function of the complex. Unraveling the complexities
of the DAP complex will be critical to understanding how
muscular dystrophies progress, and to the eventual devel-
opment of therapies.
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